Squarepoint’s BioMarin Pharmaceuticals BMRN Stock Holding History

Squarepoint’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,500	Closed	-$577K	–	4378
2025 Q2	$577K	Sell	10,500 -20,100	-66%	-$1.18M	﹤0.01%	3155
2025 Q1	$2.16M	Sell	30,600 -21,100	-41%	-$1.42M	﹤0.01%	2035
2024 Q4	$3.4M	Buy	51,700 +39,900	+338%	+$2.67M	﹤0.01%	1949
2024 Q3	$829K	Sell	11,800 -19,800	-63%	-$1.66M	﹤0.01%	2749
2024 Q2	$2.6M	Buy	31,600 +29,000	+1,115%	+$2.41M	﹤0.01%	1848
2024 Q1	$227K	Sell	2,600 -27,500	-91%	-$2.46M	﹤0.01%	3548
2023 Q4	$2.9M	Buy	+30,100	New	+$2.66M	0.01%	1755
2022 Q1	–	Sell	-6,100	Closed	-$539K	–	2847
2021 Q4	$539K	Buy	+6,100	New	+$503K	﹤0.01%	2095

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint's BMRN Position: Q1 2026 in Review

Squarepoint reduced its BioMarin Pharmaceuticals (BMRN) stake by 80% in Q1 2026, selling an estimated $85.6M and leaving 359,702 shares worth $20.3M. The position accounts for 0.02% of the portfolio, ranked #704.

Squarepoint first reported a position in BMRN in Q1 2015 and has held it in 35 quarters since. The position peaked at $109M in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Squarepoint held 359,702 shares of BioMarin Pharmaceuticals worth $20.3M as of Q1 2026.
Squarepoint sold 1,468,642 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $85.6M.
BioMarin Pharmaceuticals made up 0.02% of Squarepoint's portfolio in Q1 2026, its #704 holding.
Squarepoint first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 35 quarters since.
Squarepoint's BioMarin Pharmaceuticals position peaked at $109M in Q4 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.